GlassScriptPhysician profile
David A Alejos Castillo
NPI 1104320506
$1,748.45
in general payments reported to CMS, 2019-2025
12 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $134 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,180 · Food and Beverage: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,180.03 |
| Food and Beverage | $568.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,247.56 | 2024-2025 | |
| Exelixis INC. | $175.00 | 2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $128.10 | 2025 | |
| Eisai INC. | $55.18 | 2025 | |
| Genzyme Corporation | $22.27 | 2025 | |
| Daiichi Sankyo INC. | $20.00 | 2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $19.35 | 2025 | Opdivo |
| Pfizer INC. | $18.69 | 2025 | |
| Merck Sharp & Dohme LLC | $17.59 | 2024 | Keytruda |
| Servier Pharmaceuticals LLC | $16.49 | 2024 | |
| Iovance Biotherapeutics, INC. | $14.13 | 2025 | Amtagvi |
| Genentech USA, INC. | $14.09 | 2025 | Venclexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Alejos Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.